14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ACNB vs AACOW: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACNB vs AACOW. Trailing 12-month operating profitability (ACNB 46.4% vs AACOW N/A) and valuation multiples (ACNB 11.4x vs AACOW N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ACNB vs AACOW Key Questions & Quantitative Answers
As of Nov 20, 2026, ACNB Corp (ACNB) is the stronger overall head-to-head candidate over AACOW (AACOW) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACNB carries a Unified Composite Score of 55.4/100 (HOLD) at $64.98 (11.4x Forward P/E, 46.4% operating margin), whereas AACOW carries 48.5/100 (HOLD) at $0.32 (N/M Forward P/E, N/A operating margin). Technically, ACNB sits in a Neutral phase (RSI 45.9, UNCLASSIFIED options structure) and AACOW sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure).
ACNB leads the Growth & Scale pillar: ACNB posts +2.3% YoY revenue growth and +9.2% YoY earnings growth on $162M TTM revenue (100.0% gross margin, 46.4% operating margin), compared with AACOW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACNB generates $162M in USD-normalized revenue versus N/A for AACOW. In operating R&D and SG&A reinvestment, ACNB deploys 53.6% of Rev ($87M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AACOW.
ACNB screens cheaper on headline valuation multiples. ACNB trades at 11.4x Forward P/E, 12.0x Trailing P/E, N/M PEG, and 4.1x EV/Revenue (unreported cash flow margin), whereas AACOW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACNB (13.4% ROE) versus AACOW (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ACNB carries 27.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 20% Vol realized risk). By comparison, AACOW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 113% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.